ALSO NOTED: Rituxan aces RA, leukemia trials; Two die after Gardasil jab; Galapagos earns milestone; and much more...

> Roche's antibody med MabThera (Rituxan) just aced two trials aimed at expanding uses for the drug: one that pitted MabThera against rheumatoid arthritis and another that used it against adult leukemia. Release

> Two young women died suddenly and mysteriously after getting the Gardasil vaccine, European regulators announced yesterday. Did the vaccine precipitate their deaths? No one knows. Report

> Galapagos has achieved a milestone under its alliance agreement in rheumatoid arthritis with Johnson & Johnson's Janssen Pharmaceutica. The milestone triggered a cash payment of €3.4 million to Galapagos. Release

> Lawyers, Congressional reps, and now Senators are circling around Merck and Schering-Plough as the Vytorin brouhaha escalates into a full-blown scandal. Report

> A small clinical trial of a malaria vaccine funded by the National Institute of Allergy and Infectious Diseases has delivered positive data, triggering a move to expand the research into a second trial that enlisted 400 children in Mali. Report

> Health plans are drawing scrutiny for paying physicians to prescribe cheaper generics rather than brand-name drugs. Report

And Finally... American adults are largely ignoring a slate of important new vaccines that can prevent serious illness, according to a new survey from the National Foundation for Infectious Diseases. Report

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.